Literature DB >> 18339781

Pulmonary nodular ground-glass opacities in patients with extrapulmonary cancers: what is their clinical significance and how can we determine whether they are malignant or benign lesions?

Chang Min Park1, Jin Mo Goo2, Tae Jung Kim1, Hyun Ju Lee1, Kyung Won Lee1, Chang Hyun Lee1, Young Tae Kim3, Kwang Gi Kim4, Ho Yun Lee1, Eun-Ah Park1, Jung-Gi Im1.   

Abstract

BACKGROUND: The clinical significance of pulmonary nodular ground-glass opacities (NGGOs) in patients with extrapulmonary cancers is not known, although there is an urgent need for study on this topic. The purpose of this study, therefore, was to investigate the clinical significance of pulmonary NGGOs in these patients, and to develop a computerized scheme to distinguish malignant from benign NGGOs.
METHODS: Fifty-nine pathologically proven pulmonary NGGOs in 34 patients with a history of extrapulmonary cancer were studied. We reviewed the CT scan characteristics of NGGOs and the clinical features of these patients. Artificial neural networks (ANNs) were constructed and tested as a classifier distinguishing malignant from benign NGGOs. The performance of ANNs was evaluated with receiver operating characteristic analysis.
RESULTS: Twenty-eight patients (82.4%) were determined to have malignancies. Forty NGGOs (67.8%) were diagnosed as malignancies (adenocarcinomas, 24; bronchioloalveolar carcinomas, 16). Among the rest of the NGGOs, 14 were atypical adenomatous hyperplasias, 4 were focal fibrosis, and 1 was an inflammatory nodule. There were no cases of metastasis appearing as NGGOs. Between malignant and benign NGGOs, there were significant differences in lesion size; the presence of internal solid portion; the size and proportion of the internal solid portion; the lesion margin; and the presence of bubble lucency, air bronchogram, or pleural retraction (p < 0.05). Using these characteristics, ANNs showed excellent accuracy (z value, 0.973) in discriminating malignant from benign NGGOs.
CONCLUSIONS: Pulmonary NGGOs in patients with extrapulmonary cancers tend to have high malignancy rates and are very often primary lung cancers. ANNs might be a useful tool in distinguishing malignant from benign NGGOs.

Entities:  

Mesh:

Year:  2008        PMID: 18339781     DOI: 10.1378/chest.07-2568

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

1.  Persistent pulmonary subsolid nodules with solid portions of 5 mm or smaller: Their natural course and predictors of interval growth.

Authors:  Jong Hyuk Lee; Chang Min Park; Sang Min Lee; Hyungjin Kim; H Page McAdams; Jin Mo Goo
Journal:  Eur Radiol       Date:  2015-09-18       Impact factor: 5.315

2.  Management of subsolid pulmonary nodules in CT lung cancer screening.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

3.  Longitudinal evolution of incidentally detected solitary pure ground-glass nodules on CT: relation to clinical metrics.

Authors:  Mario Silva; Alexander A Bankier; Francesco Centra; Davide Colombi; Luca Ampollini; Paolo Carbognani; Nicola Sverzellati
Journal:  Diagn Interv Radiol       Date:  2015 Sep-Oct       Impact factor: 2.630

4.  [Management of subsolid pulmonary nodules].

Authors:  E Eisenhuber; G Mostbeck; H Prosch; C Schaefer-Prokop
Journal:  Radiologe       Date:  2014-05       Impact factor: 0.635

Review 5.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

6.  Evolution of the subsolid pulmonary nodule: a retrospective study in patients with different neoplastic diseases in a nonscreening clinical context.

Authors:  Domenico Attinà; Fabio Niro; Margherita Stellino; Federica Ciccarese; Giangaspare Mineo; Nicola Sverzellati; Maurizio Zompatori
Journal:  Radiol Med       Date:  2013-05-27       Impact factor: 3.469

Review 7.  Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Michael K Gould; Jessica Donington; William R Lynch; Peter J Mazzone; David E Midthun; David P Naidich; Renda Soylemez Wiener
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

8.  Ground glass pulmonary nodules: their significance in oncology patients and the role of computer tomography and 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Laura Evangelista; Annalori Panunzio; Elena Scagliori; Paolo Sartori
Journal:  Eur J Hybrid Imaging       Date:  2018-02-26

9.  [Value of CT Features on Differential Diagnosis of Pulmonary Subsolid Nodules and Degree of invasion Prediction in Pulmonary Adenocarcinoma].

Authors:  Fangfang Guo; Xinling Li; Xinyue Wang; Wensong Zheng; Qing Wang; Wenjing Song; Tielian Yu; Yaguang Fan; Ying Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-06-20

Review 10.  [Research progress of treatment strategy for pulmonary nodule].

Authors:  Feng Gao; Xiaojun Ge; Yanqing Hua
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.